A recent nationwide survey of 100 clinicians managing sickle cell disease has exposed a stark treatment gap. Fewer than three out of every hundred patients are recorded as having received red blood cell exchange, despite 91 % of respondents confirming that their facilities have the necessary equipment. The findings, published on 27 September 2026, highlight how logistical, financial and knowledge‑related obstacles are preventing a therapy that could markedly improve outcomes for more than 100 000 Americans living with the condition.
The Treatment That Remains Out of Reach
Red blood cell exchange works by removing damaged cells and supplementing the circulation with healthy donor blood, while preserving the patient’s own plasma, platelets and white cells. For many sufferers, this procedure can reduce painful crises and lower the risk of stroke. However, the study shows that the technology, though widely available in hospitals, is not being used at scale. Lead researcher Dr Aaron Haubner of the University of Kentucky College of Pharmacy and Terumo BCT described the situation as “exciting” therapies that are “out of reach for most patients”, emphasising the need for coordinated specialist services.
Barriers Faced by Providers and Patients
Providers reported several hurdles that limit the use of the exchange. Coordinating care between haematology, transfusion and apheresis teams often proves difficult, and the supply of compatible donor blood can be inconsistent. Only 5 % of surveyed clinicians said they encountered no obstacles, while a majority cited a general unfamiliarity with the procedure. Patients, too, face challenges: many are unaware they should ask about the therapy, and financial concerns loom large, with roughly 80 % of sickle cell patients relying on Medicaid. Geographic distribution compounds the problem, as many patients reside in rural southern states where hospitals may lack dedicated apheresis programmes.
Calls for Coordinated Care and Expanded Access
Experts are urging the creation of more comprehensive sickle cell disease centres that bring together haematologists, transfusion specialists, nurse educators and care coordinators under one roof. Dr Edward Donnell Ivy, chief medical officer at the Sickle Cell Disease Association of America, stressed that providers must be educated on national guidelines and linked through a network that shares treatment strategies. Dr Shannon Kelly, medical director of the apheresis programme at UCSF Benioff Children’s Hospital Oakland, noted that even large institutions sometimes refer patients to her centre because they lack an automated exchange service. She highlighted the hardship of travel for those who must journey long distances for essential care.
Why it Matters
The disparity between available technology and actual patient benefit underscores a broader inequity in US healthcare. Sickle cell disease predominantly affects Black and Hispanic communities, many of whom already confront socioeconomic vulnerabilities. Expanding access to red blood cell exchange would not only improve clinical outcomes but also begin to address systemic gaps in treatment provision. As the nation moves toward more integrated care models, ensuring that life‑saving therapies reach every patient—regardless of location or insurance status—becomes a critical step in reducing health disparities.
